🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Characterization of Autoreactive b Lymphocytes in Autoimmune Diseases and Immune Deficiencies

Recruitingn/aAges 18 Years - 70 YearsAllUniversity Hospital, Strasbourg, France
NCT07251179 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Autoimmune diseases (AID), whether systemic or organ-specific, affect approximately one in ten people, and their prevalence continues to increase. Many AIDs are linked to the emergence of autoreactive B cells (BCs) directed against components of the self. In healthy individuals, these autoreactive B cells are counter-selected or regulated before reaching the antibody-secreting cell compartment. However, in predisposed individuals, a breakdown in B cell tolerance can occur, leading to the formation of autoantibodies with devastating consequences, such as the emergence of systemic lupus erythematosus (SLE), rheumatoid arthritis, and vasculitis. B-cell depletion is often beneficial in these patients, but paradoxically, therapies targeting B cells are not always effective. Furthermore, B cell depletion via LB-specific antibodies (anti-CD20) or treatment with CD19 chimeric antigen receptor T

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients aged between 18 and 70 * Patients for whom at least one of the following conditions has been confirmed: * Systemic lupus erythematosus meeting the 2019 ACR/EULAR classification criteria. * Systemic scleroderma meeting the 2013 ACR/EULAR classification criteria. ANCA-associated vasculitis according to the 2022 EULAR/ACR classification criteria. * Antiphospholipid syndrome according to the 2023 ACR/EULAR criteria. * Primary immunodeficiencies according to IUIS criteria. * Patients capable of understanding the objectives of the research. * Patients affiliated with a social security health insurance scheme (beneficiary or dependant). * Patients who have signed and dated the informed consent form for non-identifying genetic testing. Exclusion Criteria: * Patient refusing to participate in the study * Patient in a period of exclusion (determined by a previous or ongoing study) Inability to provide the subject with informed consent (in an emergency or immediate life-threatening situation, difficulties in understanding the subject, etc.) * Patient under legal protection * Patient under guardianship or conservatorship
💊

What it tests

  • blood draw
📍

Where

1 site
Hôpitaux Universitaires de Strasbourg
Strasbourg, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy